Palisade Bio, Inc. (NASDAQ:PALI) Short Interest Up 38.4% in February

Palisade Bio, Inc. (NASDAQ:PALI) saw a large growth in short interest during the month of February. As of February 28th, there was short interest totalling 148,000 shares, a growth of 38.4% from the February 13th total of 106,900 shares. Approximately 5.4% of the shares of the company are short sold. Based on an average daily volume of 1,480,000 shares, the short-interest ratio is currently 0.1 days.

Palisade Bio Trading Down 13.3 %

Shares of Palisade Bio stock traded down $0.13 during mid-day trading on Monday, reaching $0.87. 380,763 shares of the stock were exchanged, compared to its average volume of 757,491. The company has a market cap of $2.40 million, a price-to-earnings ratio of -0.06 and a beta of 1.49. The firm has a 50-day simple moving average of $1.27 and a 200 day simple moving average of $2.29. Palisade Bio has a fifty-two week low of $0.75 and a fifty-two week high of $9.65.

Institutional Investors Weigh In On Palisade Bio

A hedge fund recently bought a new stake in Palisade Bio stock. JPMorgan Chase & Co. acquired a new stake in Palisade Bio, Inc. (NASDAQ:PALI) during the third quarter, according to its most recent filing with the SEC. The firm acquired 8,200 shares of the company’s stock, valued at approximately $29,000. JPMorgan Chase & Co. owned about 0.54% of Palisade Bio as of its most recent filing with the SEC. 11.79% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Brookline Capital Management assumed coverage on Palisade Bio in a research report on Wednesday, November 20th. They set a “buy” rating and a $38.00 price objective on the stock.

Palisade Bio Company Profile

Palisade Bio, Inc, a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage.